These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2491794)

  • 1. Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.
    Redman C; Lawton F; Stuart N; O'Brien M; Buxton J; Mould J; Chetiyawardana A; Crawford M; Patterson M; Sykes V
    Cancer Chemother Pharmacol; 1989; 23(1):51-3. PubMed ID: 2491794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
    Flechtner H; Queisser W; Heim ME; Henss H; Arnold H; Fritze D; Herrmann R; Fritsch H; Fritz M; Trux FA
    Onkologie; 1987 Apr; 10(2):67-71. PubMed ID: 3108738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
    Gadducci A; Brunetti I; Muttini MP; Fanucchi A; Dargenio F; Giannessi PG; Conte PF
    Eur J Cancer; 1994; 30A(10):1432-5. PubMed ID: 7833097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group].
    Verhees S; Flechtner H; Queisser W; Heim ME; Fritz M; Trux F; Edler L
    Onkologie; 1990 Feb; 13(1):50-2. PubMed ID: 1692400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.
    Alberts DS; Garcia-Kendall D; Surwit EA
    Semin Oncol; 1988 Jun; 15(3 Suppl 4):22-6. PubMed ID: 3134694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent cervical cancer with cis-platinum and mitomycin C: a phase II study.
    Malviya VK; Deppe G; Schoenmaker M
    Am J Clin Oncol; 1989 Oct; 12(5):438-41. PubMed ID: 2508464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination of 5-fluorouracil, epirubicin and mitomycin C (FEM) on advanced gastric carcinoma.
    Itoh T; Sakata Y; Tamura Y; Furukohori N; Saitoh S; Suzuki H; Tsushima K; Munakata A; Yoshida Y; Takagi S
    Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1551-6. PubMed ID: 2509606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
    Pronzato P; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso R
    Anticancer Res; 1990; 10(6):1743-5. PubMed ID: 2126683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
    Queisser W; Flechtner H; Heim ME; Kabelitz K; Massner B; Edler L
    Onkologie; 1989 Oct; 12(5):202-6. PubMed ID: 2511533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
    Papadimitriou CA; Moulopoulos LA; Vlahos G; Voulgaris Z; Kiosses E; Georgoulias N; Gika D; Diakomanolis E; Michalas S; Dimopoulos MA
    Cancer; 2000 Oct; 89(7):1547-54. PubMed ID: 11013370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
    O'Brien ME; Bayliss EJ; Stewart ME; Smyth JF; Rodger A; Leonard RC
    Cancer Chemother Pharmacol; 1990; 27(1):79-80. PubMed ID: 2123134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.
    Benedetti Panici P; Scambia G; Greggi S; Salerno G; Cento R; Mancuso S
    Oncology; 1990; 47(4):296-8. PubMed ID: 1694980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
    Toma S; Coialbu T; Biassoni L; Folco U; Gatti C; Canavese G; Giacchero A; Rosso R
    Cancer Chemother Pharmacol; 1990; 26(6):453-6. PubMed ID: 2121378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
    Topham C; Glees J; Rawson NS; Woods EM; Coombes RC
    Br J Cancer; 1991 Jul; 64(1):179-81. PubMed ID: 1906726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
    Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer.
    Currie DC; Miles DW; Drake JS; Rudd R; Spiro SG; Earl HM; Harper PG; Tobias JS; Souhami RL
    Cancer Chemother Pharmacol; 1990; 25(5):380-1. PubMed ID: 2155066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.